Providence Therapeutics Holdings Inc.: federal grants and contributions: 5 agreements; $77.1M value; 2 departments; 3 programs.
Assay record ASY-CA-1AFRSFW0LD · Cite as: Assay Systems, “Providence Therapeutics Holdings Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/providence-therapeutics-holdings-inc/
Enhancing Canadian Innovation in Biomanufacturing and R&D in mRNA Medicines
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern.
Providence Therapeutics, Canada’s leading mRNA vaccine manufacture, is manufacturing an mRNA vaccine against COVID-19. The company is in the R&D phases to demonstrate the preclinical and clinical efficacy of PTX-COVID19-B.
This proposal aims to develop a made-in-Canada solution to the threat posed by Highly Pathogenic Avian Influenza (HPAI) to Canadian livestock. Providence Therapeutics will initiate work to design and develop an mRNA vaccine drug candidate for a relevant strain using their mRNA and INTENT lipid nanoparticle (LNP) platforms.
All grants from Innovation, Science and Economic Development Canada
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.